https://www.selleckchem.com/pr....oducts/ag-120-Ivosid
00001). Patients needing intravenous therapy decreased from 23 to 5 of 26. The mean (SD) sweat chloride level decreased from a baseline of 79 (22.3) mmol/L to 65 (30.6) mmol/L, but this variation was not significant (p=0.26). No safety concerns were registered. In patients with CFTR mutations that confer RF with severe lung disease, treatment with Ivacaftor is safe and results in a clinically significant improvement that was evident at 1 month and maintained at 12 months. In patients with CFTR mutations that confer RF with sev
Like
Comment
Share
